Korea Bio-Gen Co.Ltd (318000) - Total Liabilities

Latest as of June 2026: ₩6.11 Billion KRW ≈ $4.14 Million USD

Based on the latest financial reports, Korea Bio-Gen Co.Ltd (318000) has total liabilities worth ₩6.11 Billion KRW (≈ $4.14 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Korea Bio-Gen Co.Ltd to evaluate the company's liquid asset resilience ratio.

Korea Bio-Gen Co.Ltd - Total Liabilities Trend (2017–2025)

This chart illustrates how Korea Bio-Gen Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 318000 total asset value.

Korea Bio-Gen Co.Ltd Competitors by Total Liabilities

The table below lists competitors of Korea Bio-Gen Co.Ltd ranked by their total liabilities.

Company Country Total Liabilities
Arts-Way Manufacturing Co Inc
NASDAQ:ARTW
USA $9.87 Million
Builders Capital Mortgage Corp
V:BCF
Canada CA$23.53 Million
SHINWON CONSTRUCTION COMPANY Ltd
KQ:017000
Korea ₩109.22 Billion
OURGAME INT.HOL.DL-00005
F:13O
Germany €34.30 Million
High-Tek Harness Enterprise Co Ltd
TWO:3202
Taiwan NT$3.25 Billion
Brite Tech Bhd
KLSE:0011
Malaysia RM70.81 Million
Ancora Indonesia Resources Tbk
JK:OKAS
Indonesia Rp92.74 Million
Polwax SA
WAR:PWX
Poland zł55.33 Million

Liability Composition Analysis (2017–2025)

This chart breaks down Korea Bio-Gen Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 318000 equity financing ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 6.52 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.13 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.12 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Korea Bio-Gen Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Korea Bio-Gen Co.Ltd (2017–2025)

The table below shows the annual total liabilities of Korea Bio-Gen Co.Ltd from 2017 to 2025.

Year Total Liabilities Change
2025-12-31 ₩5.42 Billion
≈ $3.67 Million
-19.39%
2024-12-31 ₩6.73 Billion
≈ $4.56 Million
+72.56%
2023-12-31 ₩3.90 Billion
≈ $2.64 Million
-52.04%
2022-12-31 ₩8.13 Billion
≈ $5.51 Million
-21.76%
2021-12-31 ₩10.39 Billion
≈ $7.04 Million
+257.63%
2020-12-31 ₩2.91 Billion
≈ $1.97 Million
+17.54%
2019-12-31 ₩2.47 Billion
≈ $1.67 Million
-72.00%
2018-12-31 ₩8.83 Billion
≈ $5.98 Million
+12.08%
2017-12-31 ₩7.88 Billion
≈ $5.34 Million
--

About Korea Bio-Gen Co.Ltd

KQ:318000 Korea Specialty Chemicals
Market Cap
$16.15 Million
₩23.84 Billion KRW
Market Cap Rank
#25867 Global
#1933 in Korea
Share Price
₩2740.00
Change (1 day)
+0.37%
52-Week Range
₩2595.00 - ₩5740.00
All Time High
₩19197.91
About

KBG Corp. produces and supplies a range of fine chemicals in South Korea and internationally. The company offers silicone chemicals, such as functional organosilanes, functional silicone polymers, silicone resins and intermediates, silicone pressure sensitive adhesives, and silicone materials for electronics; specialty chemicals, including polymerization inhibitors; and food additives, as well as… Read more